Ascendis Pharma A/S vs Moody's Corporation — how do they compare? Ascendis Pharma A/S trades at $255.5 (market cap $16.67B), while Moody's Corporation trades at $477 (market cap $82.52B). The key difference: Moody's Corporation is far larger — about 5× Ascendis Pharma A/S's market cap, and Moody's Corporation pays a 0.86% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MCO | |
|---|---|---|
Market Cap | $16.67B | $82.52B |
Sector | Health | Financials |
52-Week High | $277.18 | $539.61 |
52-Week Low | $189.74 | $412.23 |
Enterprise Value | $17.04B | $88.54B |
Dividend Yield | — | 0.86% |
Trailing returns across standard periods
Latest headlines on both assets
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →